NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis $2.81 -0.10 (-3.44%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$2.81 0.00 (0.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About SAB Biotherapeutics Stock (NASDAQ:SABS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SAB Biotherapeutics alerts:Sign Up Key Stats Today's Range$2.64▼$2.8950-Day Range$2.49▼$3.5152-Week Range$2.44▼$5.15Volume874,566 shsAverage Volume723,543 shsMarket Capitalization$253.15 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview SAB Biotherapeutics is a biotechnology company developing antibody-based medicines for autoimmune and infectious diseases. Its platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company evaluates as potential treatments. The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes. Earlier programs included antibody candidates targeting infectious diseases, such as influenza and COVID-19. SAB Biotherapeutics was founded in 2014 and is based in Sioux Falls, South Dakota. Its work focuses on research and development; the company’s products are investigational and are not established treatments.AI Generated. May Contain Errors. Read More SAB Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSABS MarketRank™: 1.902760263415 of 5 starsSAB Biotherapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 641st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSAB Biotherapeutics has a consensus price target of $12.00, representing about 327.0% upside from its current price of $2.81.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about SAB Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($1.13) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SAB Biotherapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SAB Biotherapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.96% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 8.28.Change versus previous monthShort interest in SAB Biotherapeutics has recently increased by 4.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentSAB Biotherapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SAB Biotherapeutics this week, compared to 3 articles on an average week.MarketBeat Follows5 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.39% of the stock of SAB Biotherapeutics is held by insiders.Percentage Held by Institutions7.82% of the stock of SAB Biotherapeutics is held by institutions.Read more about SAB Biotherapeutics' insider trading history. Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SABS Stock News HeadlinesSAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Consensus Price Target of $12.00November 19 at 2:44 AM | americanbankingnews.comSAB Biotherapeutics, Inc. (SABS) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17, 2026 | seekingalpha.comSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.November 22 at 1:00 AM | Base Camp Trading (Ad)FY2026 EPS Estimate for SAB Biotherapeutics Cut by AnalystNovember 12, 2026 | americanbankingnews.comSAB Biotherapeutics (SABS) Gets a Buy from GuggenheimNovember 11, 2026 | theglobeandmail.comSAB Biotherapeutics (SABS) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | fool.comSAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comSAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMSee More Headlines SABS Stock Analysis - Frequently Asked Questions How have SABS shares performed this year? SAB Biotherapeutics' stock was trading at $3.74 on January 1st, 2026. Since then, SABS shares have decreased by 24.9% and is now trading at $2.81. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. Read the conference call transcript. Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' top institutional shareholders include State Street Corp (0.82%), Soleus Capital Management L.P. (0.75%), Goldman Sachs Group Inc. (0.22%) and Alps Advisors Inc. (0.13%). Insiders that own company stock include Eddie Joe Sullivan and Michael King. View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SAB Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include NVIDIA (NVDA), IonQ (IONQ), Palantir Technologies (PLTR), Ford Motor (F), Black Diamond Therapeutics (BDTX), Bit Digital (BTBT) and Cabaletta Bio (CABA). Company Calendar Last Earnings11/05/2026Today11/22/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, SABS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CIK1833214 Webwww.sab.bio Phone(305) 845-2813FaxN/AEmployees86Year Founded2014Price Target and Rating Average Price Target for SAB Biotherapeutics$12.00 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+327.0%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$13.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.04% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.01 Current Ratio7.28 Quick Ratio7.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.34 per share Price / Cash Flow8.22 Book Value$2.34 per share Price / Book1.20Miscellaneous Outstanding Shares90,089,000Free Float83,431,000Market Cap$253.15 million OptionableOptionable Beta0.67 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SABS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.